MULTILAYERED VALIDATION OF ABCC4/MRP4 AS A THERAPEUTIC TARGET FOR PANCREATIC CANCER.

CAROZZO A; ABBA M; MOHR N; SHAYO C; GOMEZ N; YANEFF A; MONCZOR F; DAVIO C; MAY M; ITURBE J; FERNANDEZ N

Mar del Plata

Congreso; LXI Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica (SAIC). LXIV Reunión Anual Sociedad Argentina de Inmunología (SAI) y XLVIII Reunion Anual Sociedad Argentina de Farmacología Experimental (SAFE); 2016

SAIC

Pancreatic ductal adenocarcinoma (PDAC) is one of the most severe types of cancer, and because of its early development of resistance to standard therapeutic agents, and its late diagnosis, it results imperative to identify and validate new and key therapeutic targets. A lot of evidence implicates disturbances in cAMP cascade with PDAC, suggesting the oncogenic potential of this signaling pathway in this setting. In addition to the known classical mechanisms of regulation of cAMP, it was recently described its extrusion to the extracellular compartment mediated by MRP4. The aim of the present work was to validate MRP4 as a therapeutic target and characterize the role of cAMP extrusion in PDAC progression. The analysis of MRP4 expression profiles in human PDAC samples indicated higher levels of expression in tumor cells (normal tissue vs primary tumor; p